Benign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary

Size: px
Start display at page:

Download "Benign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary"

Transcription

1 Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary

2 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or mechanical, including photocopying, recording, or information storage and retrieval systems without prior written permission of Sea Courses Inc. except where permitted by law. Sea Courses is not responsible for any speaker or participant s statements, materials, acts or omissions.

3 At the end of this program, participants will be able to: Define terminology related to lower urinary tract symptoms (LUTS) Recognize and diagnose LUTS secondary to benign prostatic hyperplasia (BPH) Predict progression in terms of symptoms, acute urinary retention and need for surgery Determine the appropriate care path for each patient

4 Definition of Terms BPH Benign Prostatic Hyperplasia BOO Bladder Outlet Obstruction Hypertrophied detrusor muscle LUTS Lower Urinary Tract Symptoms Obstructed urinary flow

5 Natural History of BPH: Symptoms Worsen 30% 55% Worsen Remain Stable Improve 15% Kirby RS et al. Benign prostatic hyperplasia. Health Press,

6 ,372 French men IIEF 48% 40 35% 33% % 9% 11% 27% 9% 15% 17% 21% 30% years years years IPSS points Richard F et al., Prog Urol 2001; 11(2):

7 ED (n=853) No ED (n=3581) Diabetes 20.2% 3.2% Hypertension 32.0% 13.6% Pelvic surgery 18.8% 2.4% LUTS 72.2% 37.7% Smoker 29.6% 34.6% Regular alcohol 37.5% 42.4% Braun M et al., Int J Impot Res 2000; 12:

8 Risk Factors for BPH Progression Age 50 years or older Enlarged prostate ( 30 ml) PSA 1.4 ng/ml as a marker for prostate volume Moderate-to-severe urinary symptoms (AUA-SI score > 7) McConnell JD et al. N Engl J Med. 2003;349: Roehrborn CG et al. Urology.1999;53:

9 Clinical Outcomes in BPH vs. Other Diseases Condition Clinical Outcome Incidence (%)* Osteoporosis Vertebral fracture 1.5 Hip fracture 18 Atherosclerosis Fatal/nonfatal MI 2.1 Superficial bladder cancer Recurrence Kidney stones Recurrence 2 47 BPH AUR 7 Surgical Intervention 10 *Annual incidence or rate per person-years Adapted from Roehrborn CG et al. Urology 2000;56:9-18; McConnell JD et al. N Engl J Med 1998; 338:

10 BPH Key Components of Diagnosis: History General medical history LUTS/severity/bother; hematuria, UTI, retention, incontinence Review of nervous system (evidence of neurogenic bladder) MS, spinal cord injury DM Family history of prostate cancer Past surgical history APR, spinal surgery Urethral Surgery/instrumentation Medications Note use of diuretics, antihypertensives, psychotropics, anticholinergics, hormones, some OTC cold medications Current BPH treatment Smoking, caffeine, EtOH intake

11 BPH / LUTS Symptoms Obstructive Symptoms Irritative Symptoms Hesitancy Weak stream Straining to pass urine Prolonged micturition Post-void dribbling Sensation of incomplete bladder emptying Acute or chronic urinary retention Overflow incontinence Frequency Urgency Nocturia Urge incontinence Dysuria Hematuria *Now: Storage and voiding

12 BPH Key Components of Diagnosis: Focused Physical Exam Digital rectal examination (DRE) Assess prostate size, consistency, symmetry, presence of nodules or indurations Size does not predict severity of symptoms or obstruction Also Check for suprapubic fullness (i.e., retention) Neurologic Exam

13 BPH Key Components of Diagnosis Urinalysis Abnormalities could suggest other problems hematuria, UTI, proteinuria Discuss PSA measurement if: Age > 50, life expectancy > 10 years (diagnosis of prostate cancer would change management) Family history of prostate cancer (age 40) African American (age 40) *** Serum creatinine High creatinine necessitates imaging of upper tract

14 A Word On PSA DO NOT DO PSA IF: ACUTE RETENTION INFECTION LIFE EXPECTANCY < 10 YEARS

15 BPH - Complications If untreated, can progress to serious complications including: Acute Urinary Retention (AUR) Bladder decompensation Upper urinary tract compromise obstructive uropathy & renal failure Recurrent UTI Bleeding Stones Bladder diverticuli Decreased quality of life Anderson JB et al. Eur Urol 2001;39:

16 Treatment Options - Overview Watchful Waiting Lifestyle Modifications hs fluids, limit alcohol/caffeine, timing of diuretic use Medical Therapy - -blockers, 5- -reductase inhibitors. Surgery TURP, minimally invasive strategies

17 - Blockers

18 Alpha Blockers: General Established Mechanism of Action Blockade of sympathetic activity Relaxation of prostatic and bladder-neck smooth muscle Effects Have rapid onset of action and are well tolerated Improve urinary flow and reduce LUTS Flow rates by ~ 25% Sx Scores by 20-40% (4-6 points) Do not affect prostate enlargement or PSA *** Little effect on disease progression wrt rate of AUR/surgery Adapted from Kirby RS. Eur Urol 1999;36(suppl 1):48-53.

19 Common -Blocker Side Effects Orthostatic hypotension Dizziness (central versus vascular phenomenon) Nasal Congestion Fatigue Head-ache GI Upset RETROGRADE EJACULATION

20 1A Blockers Long-acting, Subtype Selective Tamsulosin (Flomax CR) mg 0.8mg/day Alfuzosin (Xatral) 10mg po qd Silodosin (Rapaflo) 8 mg po qd Exhibits greater uro-selectivity Selective antagonist of 1A -receptor subtype Subtype makes up ~70% of all 1 -receptors in the prostate Once daily dosing No antihypertensive properties therefore no dose adjustments are necessary

21 5- -Reductase Inhibitors

22 5-α Reductase Inhibitors (5ARI s) Type II 5AR dutasteride finasteride x x Testosterone DHT Type I 5AR x dutasteride 5-AR = 5-alpha reductase; DHT = dihydrotestosterone Prostate Size Reduced Steers WD. Urology. 2001;58(suppl 6A): Bartsch G et al. Eur Urol. 2000;37:

23 5- -Reductase Inhibitors Mechanism of action Regulates conversion of Tt to DHT Prostatic levels of DHT by 80-90% Slows rate of prostate enlargement Effects (may take 6-9mo) Decreases prostate volume by ~ 20% Reduces the risk of AUR and the need for BPH-related surgery not appropriate for men with LUTS who do not have prostatic enlargement *** Will lower PSA by 50% over 12 months

24 Indications for 5- Reductase Inhibitors Monotherapy or Combination therapy with -blocker Large prostate - men with larger prostates (> 40 g) respond more favorably (Response can be predicted by PSA - poor response if < 1.3 ng/ml) Hematuria 2 BPH

25 5ARI Efficacy: Summary Data from robust randomized placebo-controlled studies has confirmed that both dutasteride and finasteride have a significant effect in men with enlarged prostates: Reducing symptoms (30% from baseline) and impact of BPH Reducing prostate size (20-30%) Improving urinary stream (1-2 ml/sec) Reducing risk of urinary retention and surgery (>50%) Improvements are generally seen after ~6 months or more and continue to build beyond 2 years of therapy McConnell JD et al. N Engl J Med 1998;338: Roehrborn CG et al. Urology 2002; 60:

26 PSA Testing in Patients on Medical Therapy for LUTS/BPH α-blocker therapy has no effect on PSA 5α-Reductase Inhibitors lower PSA by 40-50% in 6 months Critical to have baseline PSA Refer for biopsy if elevated Repeat PSA after 6 months treatment If does not fall, indicates non-compliance or cancer risk Double PSA value to determine cancer risk Progressively rising PSA on treatment is indication for referral and biopsy

27 Combination Therapy Moderate-Severe Symptoms and Enlarged Prostate -blocker Combination 5-ARI Rapid onset Improvements in symptoms and stream Further improvement in symptoms and stream Long-lasting symptom benefit Prevent disease progression Reduce risk of AUR and surgery

28 COMBINATION THERAPY

29 Cumulative incidence of progression (%) Combination therapy is better than monotherapy at reducing risk of clinical progression McConnell JD, et al. N Engl J Med 2003;349:

30 Adjusted mean change in IPSS Combination therapy is better than monotherapy at improving symptoms Month Roehrborn CG, et al. Eur Urol Jan;57(1):

31 What to do with the α-blocker? With combination therapy, removal of the α- blocker after 6-9 months of therapy is reasonable 1,4 Majority of men will continue to enjoy good symptom control 2,3,4 More severe baseline symptoms may require that the α-blocker be continued longer-term 2 1) Nickel CJ et al. Can J Urol; 2005;12(3); ) J Barkin et al. European Urology (2003): 44; ) Baldwin KC et al: Urology 58(2), ) Nickel et al. CUAJ 2008;2(1):16-21.

32 Tadalafil 5mg currently indicated for men with BPH-related LUTS Recent clinical studies investigating PDE5- inhibitors in BPH

33 Mean change in symptom score Mean change in symptom score Mean change in symptom score Efficacy of Tadalafil Weeks Efficacy of Vardenafil Weeks Tadalafil 20 mg Efficacy of Sildenafil Weeks McVary KT, et al. J Urol Apr;177(4):

34 Mean Change in Total IPSS Score from Baseline to Endpoint Tadalafil Dosing For BPH PLA Run In Week Baseline Week 0 Week 4 Week 8 Week 12 Placebo Tad 2.5 Tad 5.0 Tad 10.0 Tad 20 Clinical meaningful improvement -9 * Tadalafil 2.5mg p<.05 at week 4, and Tadalafil 5, 10, and 20 mg p<.01 for Weeks 4, 8, and 12 compared to placebo Compared to placebo (Ancova analysis)

35 LS Mean Change from Baseline Tadalafil vs Placebo and Tamusolsin vs Placebo Baseline Week 4 Week 8 Week 12 0 Placebo -1 Tadalafil -2 Tamsulosin * * * * * * -7 *P <.05 versus placebo Study LVID

36 Some plant extracts have shown some efficacy in small clinical trials Serenoa repens (saw palmetto berry extract) Pygeum africanum (African plum)

37 Mean change in symptom score No statistically significant difference between treatment with saw palmetto and placebo Month Bent S, et al. N Engl J Med 2006;354:

38 Absolute Indications for Surgery Refractory retention Renal failure obstructive uropathy Recurrent infections Recurrent Bleeding Stones

39 BPH - When to Refer Referral warranted in patients with: IPSS > 20 (severe) Urinary retention Recurrent UTI Hematuria Bladder stones Renal insufficiency Failure of medical treatment Abnormal DRE or Elevated PSA

40 Key Messages BPH is very common in men BPH is progressive Multiple medications are available for treatment Some men will require intervention past medical therapy

MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH

MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH MANAGING BENIGN PROSTATIC HYPERTROPHY IN PRIMARY CARE DR GEORGE G MATHEW CONSULTANT FAMILY PHYSICIAN FELLOW IN SEXUAL & REPRODUCTIVE HEALTH INTRODUCTION (1) Part of male sexual reproductive organ Size

More information

Benign Prostatic Hyperplasia (BPH):

Benign Prostatic Hyperplasia (BPH): Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate

More information

Victoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine

Victoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740

More information

Prostate Disease. Chad Baxter, MD

Prostate Disease. Chad Baxter, MD Prostate Disease Chad Baxter, MD Managing BPH and LUTS Chad Baxter, MD Department of Urology cbaxter@mednet.ucla.edu 33 nd Annual UCLA Intensive Course in Geriatric Medicine & Board Review Prevalence of

More information

Benign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy

Benign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy Benign Prostatic Hyperplasia Management of Benign Prostatic Hyperplasia Goals of Therapy Improve or abolish lower urinary tract symptoms (LUTS) Prevent or delay clinical progression of benign prostatic

More information

The Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes

The Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert

More information

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP

Increasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of

More information

Diagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center

Diagnostic approach to LUTS in men. Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Diagnostic approach to LUTS in men Prof Dato Dr. Zulkifli Md Zainuddin Consultant Urologist / Head Of Urology Unit UKM Medical Center Classification of LUTS Storage symptoms Voiding symptoms Post micturition

More information

Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital

Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics. Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital Lower Urinary Tract Symptoms (LUTS) and Nurse-Led Clinics Sean Diver Urology Advanced Nurse Practitioner candidate Letterkenny University Hospital 01/02/2018 Lower Urinary Tract Symptoms LUTS - one of

More information

Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist

Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms K Kuruvilla Zachariah Associate Specialist Lower Urinary Tract Symptoms Storage Symptoms Frequency, urgency, incontinence, Nocturia Voiding Symptoms Hesitancy, poor flow, intermittency,

More information

Management of LUTS. Simon Woodhams February 2012

Management of LUTS. Simon Woodhams February 2012 Management of LUTS Simon Woodhams February 2012 The management of lower urinary tract symptoms (LUTS) in men Implementing NICE guidance May 2010 NICE clinical guideline 97 Background Lower urinary tract

More information

The Enlarged Prostate Symptoms, Diagnosis and Treatment

The Enlarged Prostate Symptoms, Diagnosis and Treatment The Enlarged Prostate Symptoms, Diagnosis and Treatment MAC00031-01 Rev G Financial support for this seminar has been provided by NeoTract, Inc., the manufacturer of the UroLift System. 1 Today s Agenda

More information

The Journal of International Medical Research 2012; 40:

The Journal of International Medical Research 2012; 40: The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment

More information

Voiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU.

Voiding Dysfunction Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU. Voiding Dysfunction 2009 Block lecture, 5 th year student. Choosak Pripatnanont, Department of Surgery, PSU. Objectives Understand and explain physiologic function and dysfunction of lower urinary tract.

More information

Office Management of Benign Prostatic Enlargement

Office Management of Benign Prostatic Enlargement Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,

More information

Benign Prostatic Hypertrophy (BPH) is the most

Benign Prostatic Hypertrophy (BPH) is the most Medical treatment of benign prostatic hypertrophy There is little doubt that medical therapy has transformed the treatment of benign prostatic hypertrophy (BPH). The medical treatment of BPH continues

More information

Key words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.

Key words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin. The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT

More information

Elements for a Public Summary

Elements for a Public Summary VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Benign prostatic hyperplasia (BPH), also called benign prostatic hypertrophy or benign prostatic obstruction, is a condition in

More information

Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano

Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano Dipartimento di Urologia Direttore Prof. Giorgio Guazzoni Mini-Invasive Treatment in Urological Diseases Dott. Alberto Saita Responsabile Endourologia Istituto Clinico Humanitas - Rozzano alberto.saita@humanitas.it

More information

Overview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014

Overview. Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia. Iain McAuley September 15, 2014 Urology Dine and Learn: Erectile Dysfunction & Benign Prostatic Hyperplasia Iain McAuley September 15, 2014 Overview Review of the most recent guidelines for ED and BPH ED Guidelines CUA 2006 AUA 2011

More information

As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder LUTS 2. Prevalence of BPH LUTS 5

As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder LUTS 2. Prevalence of BPH LUTS 5 BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG Beaconsfield Medical Practice, Brighton As man draws near the common goal Can anything be sadder Than he who, master of his soul Is servant to his bladder

More information

Male Lower Urinary Tract Symptoms: Management in primary care and beyond. Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon

Male Lower Urinary Tract Symptoms: Management in primary care and beyond. Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon Male Lower Urinary Tract Symptoms: Management in primary care and beyond Daniel Cohen PhD FRCS(Urol) Consultant Urological Surgeon 1 LUTS Very common: 1/3 men over age of 50 have moderate to severe LUTS

More information

Canadian Undergraduate Urology Curriculum (CanUUC): Prostate Diseases

Canadian Undergraduate Urology Curriculum (CanUUC): Prostate Diseases Canadian Undergraduate Urology Curriculum (CanUUC): Prostate Diseases LUTS/Benign Prostate Hyperplasia Objectives 1. List the lower urinary tract symptoms (LUTS) found in men with BPH. 2. List the differential

More information

All about the Prostate

All about the Prostate MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,

More information

10/9/2015. Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University

10/9/2015. Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University Dana A. Brown, Pharm.D., BCPS Assistant Dean for Academics, Associate Professor of Pharmacy Practice Palm Beach Atlantic University 1. Explain the pathophysiology of benign prostatic hyperplasia (BPH),

More information

Benign Prostatic Hyperplasia. Shahideh Amini Pharm.D clinical pharmacy resident Tehran university of medical science Department of pharmacotherapy

Benign Prostatic Hyperplasia. Shahideh Amini Pharm.D clinical pharmacy resident Tehran university of medical science Department of pharmacotherapy Benign Prostatic Hyperplasia Shahideh Amini Pharm.D clinical pharmacy resident Tehran university of medical science Department of pharmacotherapy Definition BPH is a common disorder that increases in frequency

More information

BPH / LUTS. Prevalence. Prevalence of BPH. It is abnormal NOT to have benign growth of the prostate with increasing age. Prevalence.

BPH / LUTS. Prevalence. Prevalence of BPH. It is abnormal NOT to have benign growth of the prostate with increasing age. Prevalence. BPH / LUTS Dr Jonny Coxon MA MD MRCS MRCGP DRCOG FECSM Beaconsfield Medical Practice, Brighton & Brighton & Sussex Universities NHS Trust As man draws near the common goal Can anything be sadder Than he

More information

EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT

EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor

More information

Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran

Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark Studies Vijayan Manogran MTOPS & CombAT PLESS SMART ALTESS ALF-ONE VA PREDICT EPICS Landmark Studies MTOPS Medical Therapy of Prostatic Symptoms

More information

Case studies: LUTS. Case 1 history. Case 1 - questions. Case 1 - outcome. Case 2 - history. Case 1 learning point 14/07/2015 DR JON REES

Case studies: LUTS. Case 1 history. Case 1 - questions. Case 1 - outcome. Case 2 - history. Case 1 learning point 14/07/2015 DR JON REES Case 1 history Case studies: LUTS DR JON REES A 49 year old male comes to see you he has had gradual deterioration of his flow over the last few years- he saw a colleague of yours 6 weeks ago who recorded

More information

50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?

50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms? PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that

More information

Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Ablation, of prostate, holmium laser, 485 495 African prune tree (Pygeum africanum), 454 455 Alfuzosin, 445 446 Alpha-adrenergic agonists,

More information

MODULE 3: BENIGN PROSTATIC HYPERTROPHY

MODULE 3: BENIGN PROSTATIC HYPERTROPHY MODULE 3: BENIGN PROSTATIC HYPERTROPHY KEYWORDS: Prostatic hypertrophy, prostatic hyperplasia, PSA, voiding dysfunction, lower urinary tract symptoms (LUTS) At the end of this clerkship, the medical student

More information

Benign Prostatic Hyperplasia (BPH)

Benign Prostatic Hyperplasia (BPH) Benign Prostatic Hyperplasia (BPH) Definition Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH), prostate gland enlargement can cause bothersome

More information

During the past decade, numerous

During the past decade, numerous Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.

More information

Management of Voiding Problems in Older Men. Dr. John Fenn Consultant, QEH 10 th October, 2005

Management of Voiding Problems in Older Men. Dr. John Fenn Consultant, QEH 10 th October, 2005 Management of Voiding Problems in Older Men Dr. John Fenn Consultant, QEH 10 th October, 2005 Voiding Problems Poor stream Hesitancy Straining Incomplete emptying Intermittent micturition Terminal dribbling

More information

LUTS A plea for a holistic approach. HUBERT GALLAGHER, MCh; FRCSI, FRCSI(Urol) Head of Urology Beacon Hospital

LUTS A plea for a holistic approach. HUBERT GALLAGHER, MCh; FRCSI, FRCSI(Urol) Head of Urology Beacon Hospital LUTS A plea for a holistic approach. HUBERT GALLAGHER, MCh; FRCSI, FRCSI(Urol) Head of Urology Beacon Hospital LUTS- Classification Men LUTS can be divided into: Storage Voiding Frequency Nocturia Urgency

More information

α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results

α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;

More information

Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia

Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia [Medicine Update (2003): 11(2), 55-58] Role of herbal drugs in the management of benign prostatic hyperplasia: Clinical trial to evaluate the efficacy and safety of Himplasia Arora, R.P., CMO, Rajiba L.

More information

Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type. Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with

More information

The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page

The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary

More information

Management of male LUTS in general practice

Management of male LUTS in general practice 17 Management of male LUTS in general practice MARK J. SPEAKMAN AND FAITH MCMEEKIN The initial management of lower urinary tract symptoms in men is usually carried out in primary care. The authors explain

More information

Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH)

Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) The Annals of African Surgery www.sskenya.org Combination Drug Therapy for Benign Prostatic Hyperplasia (BPH) Author: Oliech J.S. FRCS, Affiliation: Department of Surgery, University of Nairobi. P.O. Box

More information

Management of LUTS after TURP and MIT

Management of LUTS after TURP and MIT Management of LUTS after TURP and MIT Hong Sup Kim Konkuk University TURP & MIT TURP : Gold standard MIT TUIP TUNA TUMT HIFU LASER Nd:YAG, ILC, HoLRP, KTP LUTS after TURP and MIT Improved : about 70% Persistent

More information

Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol

Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone

More information

Alpha antagonists from initial concept to routine clinical practice

Alpha antagonists from initial concept to routine clinical practice european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice

More information

DOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI

DOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI DOWNLOAD OR READ : TREATMENT OF BENIGN PROSTATIC HYPERPLASIA PDF EBOOK EPUB MOBI Page 1 Page 2 treatment of benign prostatic hyperplasia treatment of benign prostatic pdf treatment of benign prostatic

More information

LUTS after TURP: How come and how to manage? Matthias Oelke

LUTS after TURP: How come and how to manage? Matthias Oelke LUTS after TURP: How come and how to manage? Matthias Oelke Department of Urology Global Congress on LUTD, Rome, 26 th June 2015 Disclosures Consultant, speaker, trial participant and/or research grants

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme Clinical guideline CG97: The management of lower urinary tract symptoms in men Publication date May

More information

Chapter 3: Results of the Treatment Outcomes Analyses

Chapter 3: Results of the Treatment Outcomes Analyses Chapter 3: Results of the Treatment Outcomes Analyses TABLE OF CONTENTS INTRODUCTION... 3 WATCHFUL WAITING... 11 STUDY OUTCOMES... 11 MEDICAL THERAPIES... 13 ALPHA-ADRENERGIC ANTAGONISTS (ALPHA-BLOCKERS)...

More information

Recommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol

Recommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Drug review BPH Recommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The development of safe and effective drugs

More information

Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต

Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต Prostate gland disorder พ.ต.ต.นพ.ส ร ต ก ตต ศ ภพร นพ.(สบ.2) โรงพยาบาลต ารวจ ส าน กงานต ารวจแห งชาต Prostate cancer Overview Diagnosis Treatment Lower urinary tract symptoms EPIDEMIOLOGY The most common

More information

MEDICAL THERAPY. Endocrine Approaches. Página 1 de 5.

MEDICAL THERAPY. Endocrine Approaches. Página 1 de 5. Página 1 de 5 MEDICAL THERAPY Part of "32 - BENIGN PROSTATIC HYPERPLASIA" Use of pharmacologically defined and a variety of so-called alternative medications to attempt to improve BPH voiding dysfunction

More information

VOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS

VOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS VOIDING DYSFUNCTION IN ELDERLY MALE CURRENT STATUS DR. FRANCIS LEE Voiding dysfunction Storage Emptying Common voiding dysfunction in elderly male Emptying BPH Storage Incontinence Overactive bladder Post-prostatectomy

More information

Prostate Health PHARMACIST VIEW

Prostate Health PHARMACIST VIEW Prostate Health PHARMACIST VIEW Prostate Definition Prostate is a gland made of fibromuscular tissue. It is about 4 cm and surrounds the neck of the bladder and the urethra. It produces seminal fluid.

More information

Diagnosis and Mangement of Nocturia in Adults

Diagnosis and Mangement of Nocturia in Adults Diagnosis and Mangement of Nocturia in Adults Christopher Chapple Professor of Urology Sheffield Teaching Hospitals University of Sheffield Sheffield Hallam University UK 23 rd October 2015 Terminology

More information

Medical Therapy for Benign Prostatic Hyperplasia Present and Future Impact

Medical Therapy for Benign Prostatic Hyperplasia Present and Future Impact REPORTS Medical Therapy for Benign Prostatic Hyperplasia Present and Future Impact Muta M. Issa, MD, MBA; Timothy S. Regan, BPharm, RPh, CPh Abstract The purpose of this manuscript is to provide clinicians,

More information

Month/Year of Review: May 2014 Date of Last Review: November 2012 Source Document: OSU College of Pharmacy

Month/Year of Review: May 2014 Date of Last Review: November 2012 Source Document: OSU College of Pharmacy Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights

More information

DIAGNOSED WITH BENIGN PROSTATIC HYPERPLASIA

DIAGNOSED WITH BENIGN PROSTATIC HYPERPLASIA Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 74 No. 4 pp. 1247ñ1253, 2017 ISSN 0001-6837 Polish Pharmaceutical Society PHARMACOLOGY CLINICAL EVALUATION OF α-1-adrenolytics IN PATIENTS DIAGNOSED WITH

More information

PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA

PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA St. Louis Hospital PROSTATIC EMBOLIZATION FOR BENIGN HYPERPLASIA INITIAL CLINICAL RESULTS Faculty of Medical Sciences New University of Lisbon JOÃO PISCO LUÍS CAMPOS PINHEIRO TIAGO BILHIM HUGO RIO TINTO

More information

Men s Health Topics. Learning Objectives. BPH Definition. The Prostate Gland. I have nothing to disclose. Mindi Miller, Pharm. D.

Men s Health Topics. Learning Objectives. BPH Definition. The Prostate Gland. I have nothing to disclose. Mindi Miller, Pharm. D. I have nothing to disclose Men s Health 2016 Mindi Miller, Pharm. D., BCPS Topics Benign Prostatic Hyperplasia Erectile Dysfunction Learning Objectives Describe common lower urinary tract symptoms (LUTS)

More information

PRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR

PRABHAKAR SINGH*, MANOJ INDURKAR, AMITA SINGH, PALLAVI INDURKAR Academic Sciences International Journal of Current Pharmaceutical Research ISSN- 0975-7066 Vol 5, Issue 1, 2013 Research Article COMPARISON OF THE EFFICACY AND SAFETY OF TAMSULOSIN (0.4 V/S (and) FINASTERIDE

More information

JMSCR Vol 05 Issue 07 Page July 2017

JMSCR Vol 05 Issue 07 Page July 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.47 Original Research Article Tadalafil therapy

More information

Benign Prostatic Hyperplasia A Management Update for Pharmacists

Benign Prostatic Hyperplasia A Management Update for Pharmacists A Management Update for Pharmacists Tom Smiley, PharmD This program has been approved for 1.0 CEUs by the Canadian Council on Continuing Education in Pharmacy CCCEP #1043-2010-087-I-P This lesson is valid

More information

UBC Department of Urologic Sciences Lecture Series. Voiding Dysfunction & BPH

UBC Department of Urologic Sciences Lecture Series. Voiding Dysfunction & BPH UBC Department of Urologic Sciences Lecture Series Voiding Dysfunction & BPH Objectives Today 1. Anatomy of the lower urinary tract A) Innervation of the bladder B) Normal voiding 2. Classify Neurogenic

More information

Literature Scan: Drugs for BPH

Literature Scan: Drugs for BPH Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Treating BPH: Comparing Rezum UroLift and HoLEP

Treating BPH: Comparing Rezum UroLift and HoLEP Treating BPH: Comparing Rezum UroLift and HoLEP Scott M. Cheney MD Mayo Clinic Arizona 2018 MFMER slide-1 Welcome to AZ 2018 MFMER slide-2 Outline Background on BPH, Rezum, Urolift, HoLEP AUA Guideline

More information

Neurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder.

Neurogenic bladder. Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Definition: Neurogenic bladder Neurogenic bladder is a type of dysfunction of the bladder due to neurological disorder. Types: Nervous system diseases: Congenital: like myelodysplasia like meningocele.

More information

MMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS

MMM. Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Dr Tan & Partners MMM Vol. 1 No. 1 Morbidity & Mortality Meeting 14 th November 2014 Introduction Topic The use of Tadalafil 5mg daily for the treatment of BPH-LUTS Tadalafil 5mg daily is a well established

More information

R. Matthew Smith M.D. Mercy Urology

R. Matthew Smith M.D. Mercy Urology R. Matthew Smith M.D. Mercy Urology None Disclosures Goals Update growth of Mercy Urology Clinic Quick Review of Hematuria and PSA Present common urologic complaints seen by the primary care physician

More information

Guideline for the primary care management of male lower urinary tract symptoms

Guideline for the primary care management of male lower urinary tract symptoms review Article GUIDELINES FOR LUTS M.J. SPEAKMAN et al. As my Comment in the first section of the journal suggested, the MTOPS results have offered the possibility to general practitioners of reducing

More information

Benign Prostatic Hyperplasia: Update on Innovative Current Treatments

Benign Prostatic Hyperplasia: Update on Innovative Current Treatments Benign Prostatic Hyperplasia: Update on Innovative Current Treatments Michael Ferrandino, MD As.soc Professor Director of Minimally Invasive Urologic Surgery Division of Urologic Surgery Duke University

More information

Benign Prostatic Hyperplasia (BPH) IPT VI Srikanth Kolluru, Ph.D

Benign Prostatic Hyperplasia (BPH) IPT VI Srikanth Kolluru, Ph.D Benign Prostatic yperplasia (BP) IPT VI Srikanth Kolluru, Ph.D. kolluru@tamhsc.edu, 361 221 0741 verview 1. Introduction and background of BP 2. Causes and common symptoms 3. Treatment options Learning

More information

Managing lower urinary tract symptoms in men

Managing lower urinary tract symptoms in men Managing lower urinary tract symptoms in men MacKenzie KR, Aning JJ. Managing lower urinary tract symptoms in men. Practitioner 6; 6(79):-6 Mr Kenneth R MacKenzie MBChB MRCS (Ed) Core Trainee in Urology

More information

Chapter 4: Research and Future Directions

Chapter 4: Research and Future Directions Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic

More information

GU problems of Mostly Men Notes

GU problems of Mostly Men Notes GU problems of Mostly Men Notes I. Lower Urinary Tract Infections A. Cystitis 1. Frequency, urgency, hesitancy, back pain, nocturia, suprapubic heaviness or pain 2. E coli (80%), Staph saprophyticus (5-15%),

More information

H6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)

H6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190) H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,

More information

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? available at www.sciencedirect.com journal homepage: www.europeanurology.com How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?

More information

The Neurogenic Bladder

The Neurogenic Bladder The Neurogenic Bladder Outline Brandon Haynes, MD Resident Physician Department of Urology Jelena Svircev, MD Assistant Professor Department of Rehabilitation Medicine Anatomy and Bladder Physiology Bladder

More information

NOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate

NOTE: This policy is not effective until April 1, Transurethral Water Vapor Thermal Therapy of the Prostate NOTE: This policy is not effective until April 1, 2019. Medical Policy Manual Surgery, Policy No. 210 Transurethral Water Vapor Thermal Therapy of the Prostate Next Review: December 2019 Last Review: December

More information

Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms

Systematic Review of Combination Drug Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms EUROPEAN UROLOGY 64 (2013) 228 243 available at www.sciencedirect.com journal homepage: www.europeanurology.com Platinum Priority Collaborative Review Benign Prostatic Hyperplasia Editorial by Herbert

More information

Alpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride

Alpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride European Urology European Urology 44 (2003) 461 466 Alpha-BlockerTherapy Can Be Withdrawn in the Majority of Men Following Initial CombinationTherapy with the Dual 5a-Reductase Inhibitor Dutasteride J.

More information

Policy for Prostatism/Lower Urinary Tract Symptoms in men

Policy for Prostatism/Lower Urinary Tract Symptoms in men NHS Halton Clinical Commissioning Group NHS Liverpool Clinical Commissioning Group NHS St Helens Clinical Commissioning Group NHS South Sefton Clinical Commissioning Group NHS Southport and Formby Clinical

More information

URGE MOTOR INCONTINENCE

URGE MOTOR INCONTINENCE URGE MOTOR INCONTINENCE URGE INCONTINENCE COMMONEST TYPE IN ELDERLY WOMEN Causes: 1 - Defects in CNS regulation Stroke Parkinson s disease Dementia (Alzheimer s and other types) Normopressure hydrocephalus

More information

Overactive Bladder: Diagnosis and Approaches to Treatment

Overactive Bladder: Diagnosis and Approaches to Treatment Overactive Bladder: Diagnosis and Approaches to Treatment A Hidden Condition* Many Many patients self-manage by voiding frequently, reducing fluid intake, and wearing pads Nearly Nearly two-thirds thirds

More information

EAU GUIDELINES POCKET EDITION 3

EAU GUIDELINES POCKET EDITION 3 EAU GUIDELINES POCKET EDITION 3 CONTENTS: BENIGN PROSTATIC HYPERPLASIA URINARY INCONTINENCE UROLITHIASIS 2 3 EAU POCKET GUIDELINES POCKET EDITION 3 This is one of a series of convenient pocket size books

More information

LONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA

LONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA 0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY

More information

Lower Urinary Tract Symptoms BPH vs OAB FLOW vs VOLUME. Matt T. Rosenberg, MD Family Practice Mid Michigan Health Centers Jackson, Michigan

Lower Urinary Tract Symptoms BPH vs OAB FLOW vs VOLUME. Matt T. Rosenberg, MD Family Practice Mid Michigan Health Centers Jackson, Michigan Lower Urinary Tract Symptoms BPH vs OAB FLOW vs VOLUME Matt T. Rosenberg, MD Family Practice Mid Michigan Health Centers Jackson, Michigan 1 Definition of OAB Syndrome or symptom complex defined as urgency,

More information

PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment

PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA. A Minimally Invasive Innovative Treatment PROSTATIC ARTERY EMBOLISATION (PAE) FOR BENIGN PROSTATIC HYPERPLASIA A Minimally Invasive Innovative Treatment What is the prostate? The prostate is an accessory organ of the male reproductive system.

More information

Therapeutic Strategies for Managing BPH Progression

Therapeutic Strategies for Managing BPH Progression european urology supplements 5 (2006) 997 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Therapeutic Strategies for Managing BPH Progression John M. Fitzpatrick a, *,

More information

Disclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018.

Disclosures. Geriatric Incontinence and Voiding Dysfunction. Agenda. Agenda. UI: a Geriatric Syndrome. Geriatric Syndromes 9/7/2018. Disclosures Geriatric Incontinence and Voiding Dysfunction None Shachi Tyagi MD, MS Assistant Professor Division of Geriatric Medicine University of Pittsburgh Medical Center UI: a Geriatric Syndrome Geriatric

More information

Original Article. J Fac Med Baghdad 119. Nibbras I. AL-Hamdani* Ali W. Zeki*** Introduction:

Original Article. J Fac Med Baghdad 119. Nibbras I. AL-Hamdani* Ali W. Zeki*** Introduction: Original Article The Efficacy of Solifenacin Added to Α-Adrenergic Antagonists in the Treatment of Lower Urinary Tract Symptoms in Males with Benign Prostate Hyperplasia (The Iraqi Experience) Nibbras

More information

GENDER HEALTH. Benign Prostatic Hyperplasia. Medical and Surgical Treatment Options

GENDER HEALTH. Benign Prostatic Hyperplasia. Medical and Surgical Treatment Options GENDER HEALTH Benign Prostatic Hyperplasia Medical and Surgical Treatment Options ABSTRACT Benign prostatic hyperplasia (BPH) affects the aging male. Treatment options vary widely. Some men will elect

More information

What is Benign Prostatic Hyperplasia (BPH)?

What is Benign Prostatic Hyperplasia (BPH)? What is Benign Prostatic Hyperplasia (BPH)? Benign prostatic hyperplasia (BPH) is an enlarged prostate. The prostate goes through two main growth periods as a man ages. The first occurs early in puberty,

More information

Cialis. Cialis (tadalafil) Description

Cialis. Cialis (tadalafil) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.02 Subject: Cialis Page: 1 of 5 Last Review Date: September 18, 2015 Cialis Description Cialis (tadalafil)

More information

What can the primary care physician do? Brian W. Ellis

What can the primary care physician do? Brian W. Ellis What can the primary care physician do? Brian W. Ellis Consultant Urological Surgeon at Ashford & St Peter s 1983-2007 Currently Consultant Urological Surgeon at Cobham Hospital Visiting Professor at Middlesex

More information

LUTS in the modern era. Dr Jon Rees Tyntesfield Medical Group

LUTS in the modern era. Dr Jon Rees Tyntesfield Medical Group LUTS in the modern era Dr Jon Rees Tyntesfield Medical Group In the past! Man with urinary symptoms = PROSTATISM Prostatism = TURP TURP unsuccessful = REDO TURP Redo TURP unsuccessful = can t help you!

More information

New Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital

New Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB

More information